251 related articles for article (PubMed ID: 37464963)
21. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
22. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
23. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone.
Sheng IY; Fallah J; Gupta R; Li H; Allman K; Martin A; Barata P; Ornstein MC; Gilligan TD; Rini BI; Garcia JA
Target Oncol; 2020 Aug; 15(4):477-483. PubMed ID: 32661959
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation.
Hao C; Ladbury C; Lyou Y; Manoukian S; Ruel C; Frankel P; Dorff T; Wong J; Pal S; Twardowski P; Dandapani S
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):705-710. PubMed ID: 35803445
[TBL] [Abstract][Full Text] [Related]
25. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].
Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V
Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372
[TBL] [Abstract][Full Text] [Related]
26. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM; Ramotar M; Metser U; Chung PW; Liu Z; Vines D; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):693-704. PubMed ID: 36031465
[TBL] [Abstract][Full Text] [Related]
27. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.
Tang C; Sherry AD; Haymaker C; Bathala T; Liu S; Fellman B; Cohen L; Aparicio A; Zurita AJ; Reuben A; Marmonti E; Chun SG; Reddy JP; Ghia A; McGuire S; Efstathiou E; Wang J; Wang J; Pilie P; Kovitz C; Du W; Simiele SJ; Kumar R; Borghero Y; Shi Z; Chapin B; Gomez D; Wistuba I; Corn PG
JAMA Oncol; 2023 Jun; 9(6):825-834. PubMed ID: 37022702
[TBL] [Abstract][Full Text] [Related]
28. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Freeman MN; Jang A; Zhu J; Sanati F; Nandagopal L; Ravindranathan D; Desai A; Phone A; Nussenzveig R; Jaeger E; Caputo SA; Koshkin VS; Swami U; Basu A; Bilen MA; Agarwal N; Sartor O; Burgess EF; Barata PC
Oncologist; 2022 Mar; 27(3):220-227. PubMed ID: 35274720
[TBL] [Abstract][Full Text] [Related]
29. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
31. Oncological Outcome of Combining Cytoreductive Prostatectomy and Metastasis-Directed Radiotherapy in Patients with Prostate Cancer and Bone Oligometastases: A Retrospective Cohort Study.
Xue P; Wu Z; Wang K; Gao G; Zhuang M; Yan M
Cancer Manag Res; 2020; 12():8867-8873. PubMed ID: 33061582
[TBL] [Abstract][Full Text] [Related]
32. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
[TBL] [Abstract][Full Text] [Related]
33. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
35. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
36. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
37. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.
Matsumura N; Fujita K; Nishimoto M; Minami T; Tahara H; Yoshimura K; Uemura H
World J Urol; 2023 Aug; 41(8):2063-2068. PubMed ID: 36040500
[TBL] [Abstract][Full Text] [Related]
38. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
39. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
[TBL] [Abstract][Full Text] [Related]
40. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]